
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva Inc. demonstrates a strong financial position with $178.4 million in cash and cash equivalents, alongside $76.0 million in royalty and net product sales receivables, which provide significant financial flexibility. The company's profitability is bolstered by its diverse portfolio, particularly its collaboration with GSK on respiratory products, which is critical for near-term growth. Overall, Innoviva's solid cash reserves and revenue-generating assets position it favorably for future advancements and commercial success in the healthcare sector.
Bears say
Innoviva Inc. experienced a significant non-cash charge of $90.7 million in 2Q24 due to a decline in the share price of Armata Pharmaceuticals, indicating potential volatility in its investment portfolio. Furthermore, the royalties expected from GSK agreements are projected to be lower than anticipated, posing a risk to Innoviva's revenue stream and overall financial stability. This combination of investment losses and reduced royalty income raises concerns regarding Innoviva's future performance and stock valuation.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares